Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina

Roche

Status: Completed

Conditions: Chronic Lymphocytic Leukemia

Treatments: Biological: Obinutuzumab

Study type: Observational

Funder types: Industry

Identifiers

NCT03059251

ML30187

Details and patient eligibility

About

This observational study aims to study the effectiveness and safety of Obinutuzumab in common clinical practice settings in Argentina. The study population comprises all patients with chronic lymphocytic leukemia (CLL) that have received the indication for treatment with Obinutuzumab as per routine clinical practice.

Enrollment: 2 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have received at least one dose of Obinutuzumab as per local label and clinical practice.

Exclusion criteria

• Included in clinical trial

Trial design

2 participants in 1 patient group

Obinutuzumab

Description:

All participants with chronic lymphocytic leukemia (CLL) who have received the indication for treatment with Obinutuzumab, as per routine clinical practice in Argentina.

Treatment:

Biological: Obinutuzumab